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Background: Exercise training is of benefit for patients with restrictive lung disease. However, it tends to be
intolerable for those with severe disease. We examined whether providing ventilatory assistance by using negative
pressure ventilators (NPV) during exercise training is feasible for such patients and the effects of training.
Methods: 36 patients with restrictive lung disease were prospectively enrolled for a 12-week multidisciplinary
rehabilitation program. During this program, half of them (n:18; 60.3 ± 11.6 years; 6 men; FVC: 32.5 ± 11.7%
predicted ) received regular sessions of exercise training under NPV, whilst the 18 others (59.6 ± 12.3 years; 8 men;
FVC: 37.7 ± 10.2% predicted) did not. Exercise capacity, pulmonary function, dyspnea and quality of life were
measured. The primary endpoint was the between-group difference in change of 6 minute-walk distance (6MWD)
after 12 weeks of rehabilitation.
Results: All patients in the NPV-exercise group were able to tolerate and completed the program. The between-
group differences were significantly better in the NPV-exercise group in changes of 6MWD (34.1 ± 12.7 m vs. -32.5
± 17.5 m; P = 0.011) and St George Score (−14.5 ± 3.6 vs. 11.8 ± 6.0; P < 0.01). There was an improvement in dyspnea
sensation (Borg’s scale, from 1.4 ± 1.5 point to 0.8 ± 1.3 point, P = 0.049) and a small increase in FVC (from 0.85 ±
0.09 L to 0.91 ± 0.08 L, P = 0.029) in the NPV-exercise group compared to the control group.
Conclusion: Exercise training with NPV support is feasible for patients with severe restrictive lung diseases, and
improves exercise capacity and health-related quality of life.
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Patients with restrictive lung diseases (RLD) often suffer
from dyspnea, fatigue and impairments in muscle force,
exercise tolerance, and activity of daily life (ADL), leading
to a decrease in health-related quality of life (QoL) [1-3].
This is due to a complicated combination of impairments
in ventilation and gas exchange and a number of* Correspondence: lee4949@ms41.hinet.net
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reproduction in any medium, provided the orsecondary changes such as peripheral muscle, cardiac, nu-
tritional, and psychological impairments [4]. Following the
consensus of pulmonary rehabilitation (PR) in chronic ob-
structive pulmonary disease (COPD) [5,6], evidence is
growing that patients with RLD, which share many
manifestations and physiological impairments with COPD,
may also benefit from PR. Early randomized control stud-
ies have reported an improvement in exercise capacity and
QoL after 8–10 weeks of exercise training [7,8]. The
benefits disappeared after 6 months, however this could
be overcome by longer programs extending to 24 weeks
which showed even better results [9]. Although the latterThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controlled design, the message is important. As many of
those likely to be enrolled tend to have early and profound
exercise-induced oxygen desaturation, dyspnea and per-
ipheral muscle weakness, an extended program may offset
the low initial training load [4]. Alternatively, exercise
training with some assistance, and in particular ventilatory
support, may be useful, although this has not yet been ex-
tensively tested.
Non-invasive mechanical ventilatory techniques include
the use of negative and positive pressure ventilators. Using
non-invasive positive pressure ventilators (NPPV) as an
aid during exercise training has been reported to enable a
higher intensity of training for patients with severe COPD,
leading to larger improvements in exercise performance
[10,11]. In patients with severe RLD, NPPV during exer-
cise has been shown to improve oxygenation and exercise
tolerance [12], whilst the effect on exercise training has
not been studied. Nevertheless, some practical drawbacks
such as discomfort from the mouthpiece or mask [10] can
result in a substantial number of patients dropping out
[13]. Alternatively, negative pressure ventilators (NPV)
(iron lungs) have been shown to be as effective as NPPV
in certain conditions such as acute exacerbation of COPD,
and to play a role in those who cannot tolerate a facial
mask [14]. Short-term intermittent NPV has been
demonstrated to improve ventilation and increase PaO2 in
patients with severe hypercapnic COPD [15].
We hypothesized that an exercise training PR program
with NPV support in patients with severe RLD would in-
crease exercise capacity, decrease dyspnea sensation, and
improve the QoL. We tested this hypothesis by
conducting a prospective controlled study with exercise
capacity as the primary endpoint.
Materials and methods
Subjects
This prospective, non-randomized, controlled study was
carried out from 30 November 2008 to 30 May 2010 at
Chang Gung Memorial Hospital, a university hospital in
Linko, Taiwan. All patients with severe RLD referred by
the chest physicians from the outpatient department for
pulmonary rehabilitation were eligible for inclusion if they
were clinically stable and presented with forced vital cap-
acity (FVC) ≤ 50% predicted. Patients were excluded if
they had a coexisting airway obstruction (forced expiratory
volume in one second (FEV1)/FVC ≤ 70%), other respira-
tory diseases such as asthma, tuberculosis, COPD, bron-
chiectasis, cancer, and acute infection in the last 3 months.
The decision to receive NPV-supported exercise training
was made by the chest physician after discussing the pro-
gram with the patients and their family. The protocol was
approved by the institutional review board (CGMH 97-
1032B). Each patient gave informed consent to participate.Study design
All patients attended a 12-week, twice-a-week, outpatient,
multidiscipline PR program, consisting of breathing
retraining, limb exercise training and an education program
(lectures and discussions on RLD, medication use and nu-
trition, relaxation techniques, and home exercise). The
patients in the NPV-exercise group also received endurance
exercise training consisting of 20 minutes of submaximal
cycle ergometry, combined strength/resistance training of
the upper limbs through a series of 10 repetitions against
progressive resistance, and specific training of respiratory
muscles and breathing technique exercises of the thoracic
and abdominal muscles, guided by Borg’s scale (score be-
tween 4 to 6 for dyspnea and fatigue), with the support of
NPV (control + sign model delivered by −20 cmH2O deliv-
ery pressure and +3 cmH2O base pressure, 12 cycles per
minute, inspiratory time to expiratory time (I/E) ratio 2.5).
To determine the exercise capacity, a symptom-limited bi-
cycle ergometry test as previous reported [16] was
performed using a ramp 10, 15, or 20 protocol, depending
on the patient’s fitness. The load was increased every mi-
nute by 10, 15, or 20 Watts, respectively, in such a way that
patients could reach their maximal workload within
10 minutes. The test was terminated on the basis of the
patient’s symptoms or at the physician’s discretion. Max-
imal workload in Watts at maximal performance was taken
for analysis. 40–60% of the maximal workload was used as
the intensity of training. All patients were established on an
unsupervised home endurance exercise program of 20–30
minutes walk, continuously or intermittently (in sessions
lasting 10 or more minutes) per day, guided by 40–60% of
target heart rate or 4–6 on the modified Borg scale, with
the aim of achieving 3 to 5 exercise sessions per week.
Oxygen was provided by a nasal cannula to maintain
SatO2 ≥ 90% during the whole PR course for all patients.
Clinical assessments
FEV1, FVC and FEV1/FVC were recorded using a spir-
ometer (ST-250, Fukuda Sangyo Co. Ltd.) and 6-minute
walk test (6MWT) was performed with a pulse oximeter
by a finger transducer (Criticare Systems Inc.) according
to the ATS guidelines [17,18]. The dyspnea score was
rated by patients according to a modified Borg's scale
[19], in which words describing increasing degrees
of dyspnea were assigned to numbers between 0 (no
dyspnea) and 10 ( maximal dyspnea).
Health-related quality of life (HRQoL) was assessed
using St. George’s Respiratory Questionnaire (SGRQ),
a self-administered questionnaire measuring impaired
health and perceived HRQoL for airways disease. It
consists of 76 items including symptoms, activity, impact
and total scores. The scores range from 0 (no impairment)
to 100 (the worst impairment), in which higher scores
connoted greater distress and worse HRQoL [20].
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and left extremity of the following muscle groups was
measured: extension of the knees and flexion of the elbows,
using a handheld dynamometer (Hoggan Health Industry,
West Jordon, Utah USA). The test was repeated three times,
and the best result of either side was used in the analyses.
Statistic analysis
Descriptive statistics were expressed as mean ± SD. Be-
tween group changes in pulmonary functions, 6MWD,
Borg score and SGRQ scores were analyzed using the
Mann–Whitney U test. 6MWD, FVC, FEV1 and SGRQ
at enrollment, and after 4 weeks, 12 weeks and 52 weeks
were compared using the Friedman test with Dunn’s
multiple comparison post-test for the NPV-exercise
group. SGRQ before and after the 12-week PR program
was compared by the Wilcoxon signed rank test. Data
were presented as mean ± SD. A p value less than 0.05
was considered significant. Data analyses were
performed using the GraphPad Prism 5.01 software
package (GraphPad Software, San Diego, CA).
Results
Study population
Eighteen patients (6 males and 12 females, mean age
60.3 ± 11.6 years; FVC: 32.5 ± 11.7% predicted) in the
NPV-exercise group, and 18 patients (8 males and 10
females, mean age 59.6 ± 12.3 years; FVC: 37.7 ± 10.2%
predicted) in the control group were enrolled. Before
entry into the program, most of the patients could not
tolerate exercise training without NPV support. All of
the eighteen patients in the NPV-exercise group
completed the 12-week NPV-exercise program.
The baseline characteristics of both groups are shown
in Table 1. There were no significant differences in age,Table 1 Characteristics of patients with restrictive lung





Number of patients 18 18
Age, years 59.6 ± 12.3 60.3 ± 11.6
Gender, M/F 8/10 6/12
BMI, kg/m2 19.7 ± 5.0 21.5 ± 4.6
FVC, L 1.05 ± 0.34 0.85 ± 0.37
FVC, % predicted 37.7 ± 10.2 32.5 ± 11.7
FEV1, L 0.88 ± 0.26 0.72 ± 0.32
FEV1, % predicted 42.2 ± 2.4 36.9 ± 13.6
FEV1/FVC, % 84.2 ± 8.3 83.1 ± 13.6
6MWD, m 362.8 ± 99.4 371.3 ± 77.9
Borg score, median(range) 0.5 (0–4) 1.25 (0–4)
BMI, Body mass index; 6MWD, 6-min walk distance.gender, BMI, FVC, FEV1, FEV1/FVC, 6MWD and Borg
scales between the two groups. Eight patients had chest
wall deformities and 10 patients had interstitial lung
diseases in the NPV-exercise group, while 6 patients had
chest wall deformities and 12 patients had interstitial lung
disease in the control group. Patients in both groups had
low BMI (19.7 ± 5.0 kg/m2 vs. 21.5 ± 4.6 kg/m2), poor
SGRQ scores (42.6 ± 4.6 vs. 44.6 ± 4.8) and poor exercise
tolerance (6MWD, 362.8 ± 99.4 m vs. 371.3 ± 77.9 m) with
equal severity. After the end of the 12-week study, obser-
vational data were collected for those who regularly came
back to our OPD until 52 weeks. These patients (n = 14)
were all in the NPV-exercise. The ratio between IPF and
CWD was almost unchanged at each time of evaluation,
being 10/8, 8/5, 10/8 and 7/7 at week 0, 4, 12 and 52. As
most of the patients in the control group were lost to
follow-up by 52 weeks, their clinical data were not avail-
able for analysis.
Changes in 6MWD and dyspnea sensation
Table 2 shows the effect of the PR program on 6MWT,
pulmonary function and quality of life. At the end of
12 weeks, patients in the NPV-exercise group had an in-
crease in 6MWD by 34.1 ± 12.7 m (Table 2 and Figure 1A,
371.3 ± 77.9 m vs. 405.4 ± 78.1 m; P = 0.016). In contrast,
patients in the control group had a trend of a decrease by
32.5 ± 17.5 m (362.8 ± 99.4 m vs. 330.3 ± 94.4 m; P =
0.080). The between group difference was significant
(Figure 1B, P = 0.011). The increase in 6MWD in the
NPV-exercise group started at 4 weeks, reached statistical
significance at 12 weeks, and disappeared at 52 weeks
(Figure 1C).
The improvement in 6MWD in the NPV-exercise
group was accompanied by an improvement in resting
dyspnea sensation as determined by the modified Borg
scale (Table 1, 1.4 ± 1.5 points vs. 0.8 ± 1.3 points, P =
0.049). In contrast, there was no change in Borg scale
(1.3 ± 0.4 points vs. 1.6 ± 0.4 points, P = 0.573) in the
control group. Both groups of patients suffered from O2
desaturation during 6MWT, which was not improved in
either group at 12 weeks.
Changes in pulmonary function
Pulmonary function was improved in the NPV-exercise
group after 12 weeks of training (Table 2, Figures 2A
and 3A); FVC improved by 53.3 ± 26.8 ml (0.85 ± 0.09 L
vs. 0.91 ± 0.08 L, P = 0.029), and FEV1 improved by 50.0
± 21.0 ml (0.72 ± 0.08 L vs. 0.77 ± 0.08 L, P = 0.029),
being equivalent to increases of 2.5 ± 1.0% predicted and
3.4 ± 1.2% predicted, respectively. In contrast, pulmonary
function did not change in the control group (Table 2
and Figures 2A and 3A). However, the between group
differences in either ΔFVC or ΔFEV1 did not reach stat-
istical significance (Figures 2B and 3B). Both pulmonary
Table 2 Changes in pulmonary function, 6-minute walk test, and health-related quality of life before and after
12 weeks of pulmonary rehabilitation
Non-NPV-exercise group NPV-exercise group
Baseline 12 weeks Baseline 12 weeks
(n = 18) (n = 18) (n = 18) (n = 18)
FVC, % predicted 37.7 ± 2.4 37.9 ± 3.2 32.6 ± 2.8 35.1 ± 2.7a
FEV1, % predicted 42.2 ± 2.9 43.9 ± 4.3 36.9 ± 3.2 40.3 ± 3.3
a
FEV1/FVC, % 84.1 ± 8.6 83.6 ± 7.8 82.9 ± 9.4 83.5 ± 10.8
6MWD, m 362.8 ± 99.4 330.3 ± 94.4 371.3 ± 77.9 405.4 ± 78.1a
SaO2, % pre/post 6MWT 94.0/ 81.4 93.2/ 76.8 93.9/ 77.0 94.6/ 79.1
HR, pre/ post 6MWT 98.2/ 125.8 101.4/ 127.7 103.3/ 126.7 92.0/ 123.4
Borg, pre/ post 6MWT 0.5/ 5.0 1.5/ 7.0 1.25/ 5.0 0/ 4.5a
(range) (0–4)/ (3–10) (0–4)/ (2–9) (0–4)/ (4–8) (0–4)/ (1–8)
Limb muscle power
R-upper limb, lb 32.9 ± 1.8b 32.3 ± 1.6b 31.0 ± 2.1c 33.5 ± 2.2a, c
L-upper limb, lb 30.2 ± 3.5b 33.0 ± 4.7b 29.6 ± 1.6c 30.3 ± 1.6c
R-low limb, lb 44.3 ± 3.9b 46.2 ± 4.9b 38.5 ± 3.0c 41.4 ± 2.3c
L-low limb. lb 41.2 ± 3.4b 41.3 ± 4.6b 38.2 ± 2.7c 40.7 ± 2.2c
SGRQ
Symptom score 48.2 ± 6.0e 46.5 ± 6.1e 54.6 ± 5.0 24.5 ± 4.0a
Active score 61.6 ± 6.0e 72.3 ± 6.1e 53.7 ± 5.8 45.9 ± 5.6a
Impacts score 30.0 ± 4.2e 46.7 ± 7.0a,e 36.2 ± 5.7 22.6 ± 5.1a
Total score 42.6 ± 4.6e 54.4 ± 4.9e 44.6 ± 4.8 30.0 ± 4.4a
Values are mean ± SD.
a p < 0.05, baseline vs. 12 weeks.
b only 6 patients in the non-NPV exercise group received limb muscle tests.
c 17 patients in the NPV exercise group received limb muscle tests.
e only 10 patients in the non-NPV exercise group completed the SGRQ at 12 weeks.
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crease at 4 weeks, which became significant at the end
of 12-week training program (Figures 2C and 3C).
Whilst FEV1 declined to a level similar to that at base-
line at 52 weeks (Figure 3C), the increase in FVC was
sustained at this time point (Figure 2C). The ratio of
FEV1/FVC did not change in either group at 12 weeks
compared with that at baseline (Table 2).
Changes in health-related quality of life
All the 18 patients in the NPV-exercise group completed
the SGRQ test, whereas only 10 out of the 18 patients in
the control group did. The other 8 patients did not re-
ceive the test for personal reasons. The total SGRQ
score at 12 weeks decreased by 14.5 ± 3.6 (Table 2 and
Figure 4A, 44.6 ± 20.3 vs. 30.0 ± 18.8, P = 0.009)
compared with that at baseline in the NPV-exercise
group. Improvements in SGRQ were consistently seen in
the symptom score (54.6 ± 21.0 vs. 24.5 ± 16.8, P <
0.001), the activity score (53.7 ± 24.6 vs. 45.9 ± 23.7, P =
0.048), and the impact score (36.2 ± 24.2 vs. 22.6 ± 21.6,
P = 0.077). Ten patients in the control group completed
the SGRQ. An improvement was not seen in this group,and the impact score even deteriorated (30.0 ± 13.3 vs.
46.7 ± 22.2, P = 0.04). The between group difference in
ΔSGRQ was significant (Figure 4B, P < 0.01).
Effects of NPV-exercise training vs. Control in patients
with interstitial lung disease and patients with chest wall
deformities
To see whether NPV-exercise training benefited distinct
subgroups of patients, results were separately analyzed
for patients with interstitial lung disease (ILD) and chest
wall deformities (CWD) (Table 3). FVC and FEV1
increased by 4.2 ± 4.1% predicted (36.3 ± 13.0% vs. 40.5
± 11.6%, P < 0.01) and 5.1 ± 5.5% predicted 40.9 ± 15.8%
vs. 45.9 ± 15.2%, P < 0.05) in patients with ILD in the
NPV-exercise group (n = 10). The between-group differ-
ence was significant in FVC (P < 0.01). These increases
were not seen in CDW patients in the NPV-exercise
group (n = 8). 6MWD increased by 45.8 ± 87.5 m (352.3
± 52.8 m vs. 399.5 ± 45.1 m, P < 0.05) in ILD patients in
the NPV-exercise group (n = 10). The between-group
difference was significant (P < 0.05). A trend of increase
was also seen in CDW patients (n = 8, by 17.8 ± 52.2 m,
395.0 ± 99.9 m vs. 412.8 ± 109.8 m). By contrast, both
Figure 1 Effects of NPV-exercise training vs. control on 6-minute walk distance. A. Individual changes of 6MWD in both groups before and
after the 12-week course (Control, n= 18; NPV-exercise, n= 18). B. Comparisons of delta-6MWD (Δ6MWD; changes from the base line after 12 weeks;
mean± SD) between both groups (Control, n= 18; NPV-exercise, n= 18). C. Time course of 6MWD in the NPV-exercise group (n= 14) during the 12 months.
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by 29.7 ± 74.3 m (n = 12) and 47.2 ± 54.2 m (n = 6), re-
spectively, in the control group. NPV-exercise training
improved the total scores of SGRQ in patients with ILD
(n = 10) and CWD (n =8) by 17.5 ± 18.5 (54.5 ± 21.3 vs.Figure 2 Effects of NPV-exercise training vs. control on FVC. A. Individ
course (Control, n = 18; NPV-exercise, n = 18). B. Comparisons of delta-FVC
between both groups (Control, n = 18; NPV-exercise, n = 18). C. Time cours37.0 ± 21.1, P < 0.05) and 10.9 ± 10.2 (32.2 ± 10.0 vs. 21.3
± 11, P < 0.05). This score had a trend of deterioration in
both subgroups by 1.03 ± 20.1 (n = 8) and 17.8 ± 16.6
(n = 2) in the control group. The between-group difference
was significant for ILD (P < 0.01) and CWD (P < 0.05).ual changes of FVC in both groups before and after the 12-week
(ΔFVC; changes from the base line after 12 weeks; mean ± SD)
e of FVC in the NPV-exercise group (n = 14) during the 12 months.
Figure 3 Effects of NPV-exercise training vs. control on FEV1. A. Individual changes of FEV1 in both groups before and after the 12-week
course (Control, n = 18; NPV-exercise, n = 18). B. Comparisons of delta-FEV1 (ΔFEV1; changes from the base line after 12 weeks; mean ± SD)
between both groups (Control, n = 18; NPV-exercise, n = 18). C. Time course of ΔFEV1 in the NPV-exercise group (n = 14) during the 12 months.
Figure 4 Effects of NPV-exercise training vs. control on health-related quality of life. A. Individual changes of SGRQ total scores in both
groups before and after the 12-week course (Control, n = 10; NPV-exercise, n = 18). B. Comparisons of St. George’s Respiratory Questionnaire
(SGRQ) total score (ΔSGRQ; changes from the base line after 12 weeks mean ± SD) between both groups (Control, n = 10; NPV-exercise, n = 18).
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Table 3 Changes in pulmonary function, 6-minute walk test, and health-related quality of life before and after
12 weeks of pulmonary rehabilitation in patients with interstitial lung disease vs. chest Wall disease
Non-NPV-exercise group NPV-exercise group
Baseline 12 weeks Baseline 12 weeks
FVC, % predicted
ILD 40.3 ± 10.3 38.4 ± 13.5 36.3 ± 13.0 40.5 ± 11.6b, c
Chest wall 32.7 ± 8.6 37.0 ± 14.5 28.0 ± 8.5 28.3 ± 7.4
FEV1, % predicted
ILD 45.6 ± 11.8 43.8 ± 18.2 40.9 ± 15.8 45.9 ± 15.2a
Chest wall 35.3 ±11.3 44.2 ± 20.2 31.9 ± 8.6 33.3 ± 8.0
FEV1/FVC, %
ILD 81.8 ± 6.8 84.4 ±7.9 82.3 ± 9.7 81.0 ±11.8
Chest wall 88.8 ± 10.6 82.2 ± 8.1 83.8 ± 9.7 86.6 ± 9.1
6MWD, m
ILD 385.2 ± 82.6 355.3 ± 85.0 352.3 ± 52.8 399.5 ± 45.1a
Chest wall 318.2 ± 122.4 288.0 ± 99.3 395.0 ± 99.9 412.8 ± 109.8
SaO2, % pre/post 6MWT
ILD 94.3/ 78.7 93.1/ 78.6 96.0/80.5 96.3/83.1
Chest wall 94.8/ 77.3 93.3/ 73.3 91.3/72.6 92.4/74.1
Borg, pre/ post 6MWT
ILD 0.9/ 5.1 1.5/5.8 1.7/ 5.5 0.8/4.8
Chest wall 2.0/ 5.8 1.7/5.8 1.1/ 5.3 0.8/5.0
SGRQ
Symptom score
ILD 47.6 ± 21.5c 42.1 ± 19.3c 61.7 ± 16.6e 29.5 ± 19b,e
Chest wall 50.3 ± 5.8d 64.1 ± 0.2d 53.7 ± 5.8f 45.9 ± 5.6a,f
Active score
ILD 62.2 ± 21.5 73.7 ± 12.8 61.4 ± 27.4 53.5 ± 23.2
Chest wall 59.5 ± 0.0 66.4 ± 18.8 43.9 ± 17.6 36.5 ± 22.0
Impacts score
ILD 29.3 ± 13.6 43.9 ± 19.2 48.3 ± 25.3 30.0 ± 25.3a
Chest wall 32.9 ± 16.7 58.0 ± 38.9 21.2 ± 11.7 13.5 ± 12.2
Total score
ILD 42.3 ± 16.0 52.6 ± 14.0 54.5 ± 21.3 37.0 ± 21.1a
Chest wall 43.8 ± 9.8 61.6 ± 26.4 32.2 ± 10.0 21.3 ± 11.5a
Values are mean ± SD.
a p < 0.05, baseline vs. 12 weeks; b p < 0.01, baseline vs. 12 weeks; c n = 8; d n = 2; e n = 10; f n = 8.
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The present study investigated the effect of exercise
training under the support of NPV for patients with se-
vere RLD. This study was designed in a prospective con-
trolled setting. The between group difference in
Δ6MWD, the primary end point, reached statistical dif-
ference in favor of the NPV-exercise group. An improve-
ment in SGRQ was also seen in the NPV-exercise group
compared with the control group.
Although exercise training PR programs can improve
exercise capacity and HRQoL in patients with RLD forthose with severe disease [8], it tends to be intolerable.
The patients enrolled for PR training in the present
study (FVC 32.5 ± 11.7% predicted) appeared to be more
severe than those in previous reports (FVC 48–68%
predicted) [7-9]. Almost none of the patients were able
to perform functional exercise tasks because of severe
ventilation impairment accompanied with muscle weak-
ness and deconditioning. Muscle weakness can be over-
come by ventilation support as demonstrated by Borel et
al [12]. With the assistance of NPV, all patients in the
study group well tolerated the exercise PR program, and
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in 6MWT between groups 66.6 m) than those
demonstrated in earlier reports (35.0–46.3 m) [7,8]. This
difference is greater than the minimal clinical important
difference (MCID) for COPD (54 m) [21] and that for
idiopathic pulmonary fibrosis (24–45 m) [22]. Neverthe-
less, our patients comprised a heterogeneous group of
patients with different diseases, for most of which the
MCID has not been defined. Whether the improvement
in exercise capacity reaches clinical significance needs
further study to confirm.
Ventilation support by using NPPV can unload ventila-
tor muscles, leading to a reduction in breathing work
and dyspnea sensation [23]. This unloading has also
been demonstrated to improve peripheral muscle oxy-
genation in the absence of changes in systemic oxygen
delivery in patients with advanced COPD during high-
intensity exercise, probably due to redistribution of car-
diac output to appendicular muscles [24]. This will not
only allow a greater intensity of exercise but also allow it
to be sustained for longer periods to achieve a training
effect [11]. Although not proven directly, NPV may also
benefit patients with severe RLD through similar
mechanisms such that patients may be able to tolerate
exercise training to an extent of adequate intensity.
Increased peripheral muscle oxygenation may also con-
tribute to a better training efficacy. Although more data
is necessary to support this theory, this concept may be
a rationale to introduce NPV during exercise training
for patients with RLD with less severity, or even other
respiratory diseases such as COPD.
The present study showed that an NPV-assisted exer-
cise program remarkably improved health-related quality
of life (HRQoL), as demonstrated by the SGRQ scores.
Patients in the NPV-exercise group had clinically signifi-
cant decreases in total and almost all components of the
scores, e.g. symptoms, activity and impact. This is con-
sistent with most previous reports observing the effects
of exercise training on HRQoL in a range of RLD using
the Chronic Respiratory Disease Questionnaire [8,9] or
the SGRQ [7]. Both resting and post-exercise dyspnea
sensation, determined by the Borg score, also improved.
This improvement was not associated with changes of
muscle power or O2 saturation. Interestingly, we
observed a significant increase in pulmonary function,
including FEV1 and FVC, after 12 weeks of training. Im-
portantly, the increase in FVC (2.5% predicted) reached
the recently defined minimal clinical important differ-
ence for IPF [25], in which the small changes of 2–6%
were thought to be clinically important. This was not
seen in previous reports on exercise training for RLD
patients [8,9]. Further study is needed to see whether
this improvement in pulmonary function has clinical sig-
nificance. Of note, Smith et al. reported their experienceof treating kyphotic patients with nocturnal non-invasive
ventilation, either with an individually constructed cuir-
ass shell and a negative pressure pump or nasal intermit-
tent positive pressure ventilation, long-term use of
which resulted in a significant increase in FEV1 and FVC
[26]. As the between group difference in FVC in the
present study, albeit with a trend, was not statistically
significant, further studies enrolling more patients is ne-
cessary to confirm our observations.
The present study did not include a group of NPV
without endurance training. It is therefore not conclu-
sive whether the study group got benefits from NPV
and/or exercise training. Guzun et al. recently reported
that physical training at mild intensity, even below the
level expected for a physiological training effect, can in-
duce comparable changes in skeletal muscles oxidative
energy metabolism in patients with COPD and sedentary
healthy subjects [27]. Thus it is interesting to conduct a
study to explore the pure effect of NPV or NPV with
physical activity of mild intensity.
A limitation of the study is the non-randomized de-
sign. This is dictated by the fact that few patients were
willing to be randomized in such kind of intervention.
Nevertheless, the baseline characteristics were similar
between the two groups such that a skewed population
in each group, although cannot be completely excluded,
became less likely. In addition, there is heterogeneity of
patients. Subgroup analysis revealed that NPV-exercise
training benefited both ILD and CWD patients in
HRQoL. Whereas this training improved exercise cap-
acity and pulmonary functions in ILD patients, it only
had a trend of improvement (exercise capacity) or no
effects (pulmonary functions) in CWD patients.
Whether this training has clinically relevant effects on
exercise capacity in these patients needs to be confirmed
in a larger scale of study.
Conclusions
Ventilation support with NPV during exercise training is
feasible for patients with severe RLD who are profoundly
intolerant to exercise. In such patients, exercise training
with NPV support increases exercise capacity and
HRQoL to a level of clinical importance, at least in
patients with ILD. Thus, NPV should be considered for
patients with severe RLD who are not able to tolerate
exercise training with adequate intensity. Our study also
raises the possibility that NPV enhances the training ef-
fect of exercise through redistribution of cardiac output
to the limb muscles, and that NPV increases pulmonary
functions. Further studies to confirm these findings are
warranted and may potentially extend the use of NPV in
pulmonary rehabilitation for patients with RLD, and po-
tentially for other chronic conditions with impairment in
exercise tolerance.
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